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Bezard and colleagues [1] have to be congratulated on their
studies and discussions of the mechanisms involved in
compensation of striatal dopamine loss in Parkinson’s
disease (PD). To understand how PD begins and
progresses is a major requirement in developing
more definitive therapies for PD (A.E. Lang and
J.A. Obeso, unpublished). Bezard et al. have conclusively
shown that classically accepted dopamine-mediated mech-
anisms are not primarily involved in the initial compen-
sation of striatal dopamine depletion in PD [1]. They
proposed a series of functional compensatory changes
within and outside the basal ganglia. We would like to
discuss an alternative hypothesis for the onset of PD and
the role of compensatory changes. Before that, some
methodological comments are also pertinent. The Bor-
deaux group has established an N-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) monkey model
that provokes a full parkinsonian syndrome within
three weeks, unlike PD, which develops over several
years. Importantly, PD has a unilateral or asymme-
trical onset whereas MPTP-intoxicated monkeys
exhibited bilateral symptoms from the beginning.
Both differential features of the model are relevant
when analysing the onset of PD and initial
compensatory mechanisms.
We propose that cell loss occurs asymmetrically in
the substantia nigra pars compacta (SNc) in the initial,
presymptomatic stage. This leads to a reduction in the
dopamine-mediated innervation and functional modu-
lation of the subthalamic nucleus (STN) (Figure 1a,b),
inducing STN neuronal hyperactivity before significant
dopamine striatal depletion [2,3]. At this time (in the
presymptomatic state), dopamine loss in the caudal
putamen is still not large enough (,50%) to increase
activity in the striatal inhibitory projection to the
globus pallidus pars externa (GPe). As a result,
increased STN activity exerts a powerful excitatory
effect on the GPe. Excitation of the GPe leads to
increased inhibition of the globus pallidus pars interna
(GPi) and maintains the output of the motor circuit
within normal limits. In that fashion, the ‘internal’
STN–GPe–GPi circuit compensates itself [4].
Increased STN activity could increase GPi firing by
its direct excitatory projection [5] but this can be
compensated by the still-normal ‘direct’ striatopallidal
(i.e. to the GPi) inhibitory projection. As the
neurodegenerative process progresses, striatal dopa-
mine deficit becomes high enough (i.e. 70%) to inhibit
the GPe, diminishing its inhibitory output onto the GPi
and STN (Figure 1c). At this stage, the compensatory
mechanisms keeping the GPi output activity within
normal limits fail and, consequently, the STN–GPi
circuit becomes pathologically overactive and parkin-
sonian symptoms are clinically obvious. In PD, where
the changes occur slowly, excessive STN drive onto the
GPi might also be compensated by way of the nigro-
pallidal dopaminergic projection, which has been
shown by fluorodopa positron emission tomography
(PET) to increase during the presymptomatic phase [6].
In addition, the contralateral hemisphere probably
plays an essential compensatory role, so that abnormal
GPi output onto the thalamocortical projection can be
compensated by the still-normally-operating basal
ganglia. This is supported by PET data showing a
36% reduction in fluorodopa uptake by the hemisphere
contralateral to the clinically unaffected caudal putamen
in recently diagnosed patients (i.e. what appears to be
normal on clinical grounds is shown to be abnormal by
PET). It appears that clinical manifestation requires not
only derangement of basal ganglia mechanisms in the
primary affected side but also dopamine depletion in the
secondarily affected side. Our interpretation does not
completely fit with the physiological data of Bezard et al.
[3], particularly the lack of change in firing rate of GPe
neurons throughout MPTP administration. However, phys-
iological studies in chronically intoxicated MPTP monkeys
and PD patients have shown reduced neuronal firing in the
GPe [7]. The major limitation of our hypothesis is basing the
origin of the initial stages of PD on the hyperactivity of
the STN and its disinhibition by a direct dopamine deficit. It
could be that parallel derangement of several dopaminergic
projections occurs quasi-simultaneously. Given the large
cellular heterogeneity of the substantia nigra [8], early
degenerationofespeciallyvulnerabledopaminergicneurons
that reach the motor putamen but that also branch, via axon
collaterals, within the STN, globus pallidus and other
glutamatergic nuclei (e.g. the pedunculopontine and cen-
tromedian–parafascicular nuclei), could be responsible for
the hitherto unexplained increased in STN activity preced-
ing striatal dopamine depletion. Appropriate definition of
the relevance of the different compensatory mechanisms is
very important for promoting new treatments for PD. This
could be feasible by using a methodology similar to the oneCorresponding author: Jose A. Obeso (jobeso@unav.es).
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put forward by Bezard et al. [1,3] but that induces SNc
damage much more slowly and asymmetrically.
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Obeso and colleagues address several issues [1], two of
which are particularly relevant. The first, and most
crucial, issue with regard to the findings reported in our
initial review [2] relates to the non-human-primate model
of Parkinson’s disease (PD) we have developed to
investigate compensatory mechanisms. The criticism is
essentially that, in our model, chronic administration of
low-dose N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) produces uniform striatal dopaminergic denerva-
tion [3]. This is also reported for acute intoxication with
high MPTP doses in both monkey [4] and human [5]. We
acknowledge that, although our model makes significant
advances over previous ones in terms of showing pro-
gression, in this respect it diverges from the clinical
situation, in which subdivisions within the human sub-
stantia nigra pars compacta (SNc) [6] are differentially
affected by progression of the disease [7,8]. The difference
might reflect differences in the site of the initial trigger for
degeneration in the model versus PD (i.e. striatal versus
SNc). It has been suggested that in PD there is a
mesencephalic origin for the pathological process [9], but
that different sensitivity of different localities within
SNc and ventral tegmental area (VTA) that have different
projection zones leads to a gradient in dopamine
depletion, with a higher loss in dorsal and caudal parts
of the putamen than in the caudate nucleus. However,
because the active metabolite of MPTP is taken up by
the dopamine transporter which is distributed homo-
geneously across the striatum, MPTP leads to a more
uniform striatal denervation [10]. Further understand-
ing of mechanism of neuronal death in PD will be
required before developing a new model that mimics the
details of the pattern of degeneration. In any case, the
real issue is whether the lack of a PD-like pattern of
degeneration has an impact on the interpretation of
our findings with respect to identification of novel com-
pensatory mechanisms. We believe not. Compensation
will occur as dopamine is lost in the striatum and the
effects of that loss are propagated through the circuit. In
the case of this model, such compensation will not be
subject to topographical variation but might well be
uniformly spread across the circuit. The uniformity of
the depletion could actually work in favour of the model,
making it possible to define presymptomatic compensa-
tory changes clearly.
The above notwithstanding, Obeso et al. raise a very
interesting point relating to the potential functional
consequences of the asymmetric loss of dopamine in PD
and how lack of such asymmetry might have an impact on
the interpretation of our data. They propose that in PD,
asymmetric degeneration could lead to loss of dopamine
input to the STN before significant striatal loss and that this
leads to a compensatory STN overactivity that drives the
remaining dopaminergic cells to release more dopamine.
However, although conceptually appealing, the hypothesis
is not supported by experimental evidence. In fact, the STN
has been shown to receive dopaminergic fibers [11,12] that
originate from throughout the SNc–VTA complex [13]. This
projection is actively spared in parkinsonian monkeys
[14–17]. It is, thus, hard to reconcile these findings with
an early loss of dopamine-mediated control of STN. More-
over, of great interest is the recent finding that dopamine
actually potentiates burst-firing in STN neurons through
the activation of D5 receptors [18]. A loss of dopamine in the
STN would thus notnecessarily lead toan increased activity.
In fact, we would propose that, because dopamine input to
the STN is relatively spared, because dopamine provokes
burst-firing inSTNneuronsandbecauseburst-firing isakey
feature of pathological STN activity in both MPTP monkeys
[19] and PD patients [20], it is unlikely that (i) a specific loss
of STN dopamine input occurs in presymptomatic PD, and
(ii) this loss is compensatory. By contrast, the relative
sparing of the pathway could contribute to symptomCorresponding author: Erwan Bezard (erwan.bezard@umr5543.u-bordeaux2.fr).
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